Hippocratic AI, the first Large Language Model (LLM) designed specifically for healthcare, announced its Founding Partner Program with 10 health systems and digital health companies.
Partners will help ensure the safety of Hippocratic AI’s LLM over the course of their five-year partnerships; they will guide the development of the model, participate in data governance and model safety committees, establish use cases, engage their medical professionals in conducting RLHF, and validate clinical and patient safety.
In addition, some partners have also chosen to invest in Hippocratic AI, bringing the company’s total funding to-date to $65 million. As shareholders, they will have additional oversight of the model.As shareholders, they will have additional oversight of the model.
A new phase 1 trial demonstrates the safety and effectiveness of personalized neoantigen DNA vaccines, showing promising immune responses and improved recurrence-free survival in high-risk
Hippocratic AI Launches Founding Partner Program
by Fred Pennic Leave a Comment
What You Should Know:
Partners include:
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients
A new phase 1 trial demonstrates the safety and effectiveness of personalized neoantigen DNA vaccines, showing promising immune responses and improved recurrence-free survival in high-risk
“We’re Going to See Demand for This Go Through the Roof”: VA Under Secretary for Health Shares How the Agency Is Preparing for MDMA, Psilocybin Therapies – Psychedelic Alpha
The VA has been warming up to psychedelic research and the potential roll-out of psychedelic therapies, if approved by the FDA, for the past few
C4 Therapeutics cuts staff, restructures to focus on lead protein degradation programs, discovery pacts
With Phase I data on its top degrader candidates in sight, C4 Therapeutics is letting go of 45 staffers — or 30% of the company